The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava to treat wet age-related macular degeneration (wet AMD).
- Lancet study illustrates drug delivery “milestone” June 12, 2025
- FDA grants new approval for novel hepatitis drug June 11, 2025
- Construction begins on new WuXi microbial manufacturing site June 10, 2025
- Multi-billion-pound funding to accelerate UK’s high-growth sectors June 9, 2025
- Duchenne gene therapy interim trial outcomes “striking” June 6, 2025
- MHRA issues first UK guidance on phage therapies June 5, 2025
- Sandoz Launches PYZCHIVA® (Ustekinumab) Autoinjector in Europe June 4, 2025
- Samsung Bioepis Secures Marketing Approval in Korea for its Biosimilar to Amgen’s Bone Cancer Drug Xgeva June 3, 2025
- EMA Issues Positive CHMP Opinions for Fresenius Denosumab Biosimilars June 2, 2025
- Celltrion, Samsung Bioepis, and Organon Receive Interchangeability Designations for Adalimumab Biosimilars June 2, 2025
- FDA Approves Bio-Thera and Hikma’s Ustekinumab Biosimilar May 29, 2025
- The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip June 10, 2025
- Moving Beyond Mitigation: Cracking the Maximizer Code to Protect Patient Affordability June 6, 2025
- Pharmacist Salaries and Employment in 2024: Retail Employment Collapse Offset by Hospital Boom June 3, 2025
- Three Ways GoodRx Is Helping Pharmacies Increase Profitability and Drive Innovation May 30, 2025
- Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress May 28, 2025
- How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs May 21, 2025
- What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar) May 20, 2025